Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with Chemotherapy in Metastatic Pancreatic Cancer
NCT02879318Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Nov 2016
- Primary completion
- Aug 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in pancreatic adenocarcinoma (PDAC), sponsored by Canadian Cancer Trials Group. Started Nov 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02879318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879318.